Table 2

 Secondary treatment outcomes according to assigned treatment

Secondary outcomesPlacebo (n = 19)BoNT-A (n = 20)Mean difference (95% CL)p Value*
Baseline8 weeksChangeBaseline8 weeksChange
BoNT-A, botulinum toxin type A; VAS, visual analogue scale.
Values are mean (SD).
*Unpaired t test.
VAS handwriting (points)1.78 (1.39)2.31 (1.49)0.53 (1.51)1.70 (1.20)3.55 (1.93)1.85 (1.54)1.32 (0.33/2.31)0.01
Symptom severity scale (points)27.32 (4.57)26.16 (4.30)−1.16 (3.18)28.10 (4.67)24.50 (6.02)−3.60 (3.20)−2.44 (−4.52/−0.37)0.02
Functional status scale (points)8.95 (5.41)7.53 (3.95)−1.42 (1.87)10.25 (7.02)10.90 (7.93)0.65 (5.00)2.07 (−0.40/4.54)0.10
Writer’s cramp rating scale (points)4.47 (1.84)3.68 (1.16)−0.79 (1.40)4.50 (1.96)2.20 (1.88)−2.30 (1.78)−1.51 (−2.55/−0.47)<0.01
Writing speed (lines)7.93 (3.20)8.20 (2.90)0.27 (1.33)7.59 (2.80)9.00 (2.38)1.41 (1.91)1.14 (0.07/2.20)0.04